Jose Martinez, MD
Ophthalmology · Austin, TXNPI 1679545370
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,301 of the $42,823 with a category attached, or 80.1%. Regeneron Healthcare Solutions, Inc. accounts for 87.8% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $14,109 and has fallen 78.9% since, to $2,980 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 90 payments — averaging $475.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$38K
- US Retina LLC$2K
- Regeneron$746
- AbbVie$625
- Apellis Pharmaceuticals, Inc.$584
- Genentech USA, Inc.$353
- plus $1K from 14 others
Across 2 payments — averaging $4050.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mallinckrodt Enterprises LLC$6K
- Mallinckrodt Hospital Products Inc.$2K
What the payments were for
- Consulting fees$3781%
- Speaking & faculty fees$34,30180%
- Grants$5001%
- Travel & lodging$2,5806%
- Food & beverage$3,2368%
- Education$930%
- Gifts$1760%
- Ownership interest$1,5604%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 28 | $37,589 |
| US Retina LLC | 6 | $1,560 |
| Regeneron | 8 | $746 |
| AbbVie | 3 | $625 |
| Apellis Pharmaceuticals, Inc. | 6 | $584 |
| Genentech USA, Inc. | 14 | $353 |
| Genentech, Inc. | 3 | $241 |
| Aerie Pharmaceuticals, Inc. | 2 | $240 |
| Carl Zeiss Meditec, Inc. | 1 | $176 |
| Mallinckrodt Enterprises LLC | 1 | $119 |
| Mallinckrodt Hospital Products Inc. | 2 | $109 |
| Biotissue Holdings Inc. | 1 | $106 |
| Astellas Pharma US Inc | 3 | $94 |
| Eyepoint US, Inc. | 1 | $80 |
| Biogen | 4 | $60 |
| Bausch & Lomb Americas Inc. | 2 | $48 |
| Novartis | 2 | $39 |
| Neurotech Pharmaceuticals, Inc. | 1 | $26 |
| Alimera Sciences, Inc. | 1 | $17 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$42,823 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 45 | $3,897 |
| Ketorolac Tromethamine | 51 | $1,114 |
| Prednisolone Acetate | 34 | $1,058 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 54 | $588 |
| Latanoprost | 27 | $141 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 18 | $134 |
| Timolol Maleate | 19 | $91 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Austin
- Chirag JhaveriAustin$240K
- Sheila BarbarinoAustin$232K
- Aaron RollerAustin$202K
- Philip StoreyAustin$161K
- Robert WongAustin$113K
- Farhan IrshadAustin$111K
- Edward WoodAustin$110K
- Ryan YoungAustin$105K
- Steven DellAustin$94K
- Shelley GhafooriAustin$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.